WellPoint/Amerigroup Merger Okayed, New Acura Product News: Healthcare Business Recap

The Justice Department is no longer concerned over the possible creation of a Medicaid managed care monopoly in most of Northern Virginia and has cleared the way for the health insurer WellPoint (NYSE:WLP) to purchase Amerigroup Corporation (NYSE:AGP). The change in the DOJ’s attitude came with Amerigroup agreeing to divest its Virginia business, Amerigroup Virginia Inc., to the Inova Health System Foundation which is contingent upon the above $4.46 billion merger to occur.

Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.

Acura Pharmaceuticals (NASDAQ:ACUR) has developed a next-generation pseudoephedrine formulation which will impede the extraction of pseudoephedrine from the tablets to form methamphetamine. Nexafed unites nasal-congestion relief with unique IMPEDE tech which disrupts the conversion of pseudoephedrine into methamphetamine. According to topline results from a phase 1 pharmacokinetic study in 30 healthy adult subjects, Nexafed is bioequivalent to the leading national brand product and the medication should be launched before the year’s end. In response, shares of Acura had gained more that 35 percent in late afternoon trading.

Don’t Miss: These Retailers Rip Higher After Quarterly Results.


To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Premium Newsletters

Stock Investor Cheat Sheet

Stock Investor Cheat Sheet®

The ultimate Cheat Sheet for finding winning stock picks.
Learn More

Gold & Silver Newsletter

Gold & Silver

Don't miss one of the biggest bull markets in history! Covers Gold, Silver, Gold & Silver stocks, and miners.
Learn More

Commodities Premium Newsletter

Commodities Premium

There's always a bull market in some sector! Find the best opportunities in commodities.
Learn more

ETF Investing

ETF Investing

At last, a trading system that buys the right ETFs at the right time, time after time!
Learn more

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business